Lipocine announces last patient visit in Phase 3 trial of LPCN 1154

Lipocine (LPCN) announced that the last patient has completed the final study visit in its Phase 3 clinical trial evaluating LPCN 1154 for the treatment of postpartum depression. The randomized, double-blind, placebo-controlled study enrolled a total of 90 patients with severe PPD, having an average baseline Hamilton depression rating scale of 28.3. LPCN 1154 has shown a positive safety profile, with all reported nervous system adverse events being mild to moderate in severity. Furthermore, there were no instances of drug discontinuation, excessive sedation, loss of consciousness, or drug-related serious adverse events.